During the last 15 years of his more than 30 years in the industry, Alexander held C-level positions at leading global companies as Sun Pharmaceuticals and Merz Pharmaceuticals. Alexander is also co-founder and Executive Chairman of US-based Galimedix Therapeutics. Alexander studied medicine at Gutenberg University in Mainz, Germany where he gained his doctor's degree in experimental pharmacology. He also holds a degree in computer science and lectures pharmacoeconomics.

Konstantin brings strong industry experience and a solid track record of growing and expanding businesses. He has been responsible for major business development deals, including licensing / co-development agreements and strategic alliances, and brings extensive knowledge of portfolio strategy development, marketing and sales.

Konstantin has a PhD in oncology from the Ludwig-Maximilians-University, Munich, Germany and holds an MBA from the University of Applied Sciences for Economics and Management.  He also completed post-graduate studies in market access at the Health Care Management Institute of the European Business School.

Frank’s therapeutic expertise is rooted in the fields of oncology and metabolic diseases. He has profound knowledge in conceptualizing, developing and evaluating ASO-based, targeted therapies, playing a central role in establishing new, high value ASO pipelines in the course of his career. Before joining Secarna, Frank worked in scientific leadership positions at Antisense Pharma/Isarna Therapeutics and The Genetics Company.

Frank is an active contributor to the international scientific and biopharmaceutical discovery and development community and his and his team’s work is recognized at international conferences and in major peer-reviewed publications.

Richard has over 15 years of experience in the field of immunology/immunooncology and has focused his research on the identification of novel therapeutic approaches to treat patients with cancer. With his doctoral studies and a Postdoc in translational immunotherapy at the Klinikum rechts der Isar (TU München), he has built extensive knowledge in this field.

Richard studied biology at Regensburg University and holds a doctor’s degree in immunology. He has a track record in bringing novel discoveries to the scientific community, with several approved patents and 15+ peer-reviewed publications.